15 Jul Foundation for Angelman Syndrome Therapeutics
Posted at 19:29h
in
Allyson Berent, Chief Scientific Officer, Foundation for Angelman Syndrome Therapeutics; Chief Development Officer. Co-founder, AS2Bio
Oct. 5 | 9:45am | FLW Ballroom F
Austin, TX
(Private)
FAST, a non-profit patient advocacy organization launched an accelerator called AS2Bio, a venture philanthropy model to advance platform agnostic and disease specific therapies forward for the rare monogenic disorder called Angelman syndrome, serving as a platform for other rare monogenic neurodevelopmental disorders.